CC
MCID: CHL127
MIFTS: 54

Cholangiocarcinoma, Susceptibility to (CC) malady

Categories: Genetic diseases, Liver diseases, Rare diseases, Cancer diseases, Gastrointestinal diseases

Aliases & Classifications for Cholangiocarcinoma, Susceptibility to

About this section
Sources:
11Disease Ontology, 13DISEASES, 24GeneTests, 25Genetics Home Reference, 27GTR, 30ICD10, 31ICD10 via Orphanet, 35LifeMap Discovery®, 39MeSH, 40MESH via Orphanet, 45NCIt, 50Novoseek, 52OMIM, 54Orphanet, 62SNOMED-CT, 68UMLS, 69UMLS via Orphanet
See all MalaCards sources

Aliases & Descriptions for Cholangiocarcinoma, Susceptibility to:

Name: Cholangiocarcinoma, Susceptibility to 52 35
Cholangiocarcinoma 35 11 24 25 54 27 50 13 68
Adult Primary Cholangiocellular Carcinoma 11 68
Intrahepatic Cholangiocarcinoma 25 68
Extrahepatic Cholangiocarcinoma 25 68
Cholangiocarcinoma of Biliary Tract 25
Adult Primary Cholangiocarcinoma 11
 
Cholangiocellular Carcinoma 25
Bile Duct Carcinoma 68
Bile Duct Cancer 54
Cholangiosarcoma 11
Cca, Icca, Icc 24
Cca 54
Cc 25

Characteristics:

Orphanet epidemiological data:

54
cholangiocarcinoma:
Inheritance: Not applicable; Prevalence: 1-9/100000 (Worldwide),1-9/100000 (Europe); Age of onset: Adult

Classifications:

Orphanet: 54 
Rare hepatic diseases


External Ids:

OMIM52 615619
Disease Ontology11 DOID:4947
ICD1030 C22.1
MeSH39 D018281
NCIt45 C4436, C8265
SNOMED-CT62 312104005, 70179006
Orphanet54 ORPHA70567
ICD10 via Orphanet31 C24.8, C24.9, C22.1 C24.0, more
MESH via Orphanet40 D001650, D018281
UMLS via Orphanet69 C0206698, C0740277

Summaries for Cholangiocarcinoma, Susceptibility to

About this section
OMIM:52 Carcinomas of the biliary tract are aggressive malignancies, with 5-year survival of less than 10%. These carcinomas... (615619) more...

MalaCards based summary: Cholangiocarcinoma, Susceptibility to, also known as cholangiocarcinoma, is related to klatskin's tumor and colorectal cancer, and has symptoms including abdominal pain, malaise and abdominal pain. An important gene associated with Cholangiocarcinoma, Susceptibility to is PTPN3 (Protein Tyrosine Phosphatase, Non-Receptor Type 3), and among its related pathways are Listeria monocytogenes entry into host cells and a6b1 and a6b4 Integrin signaling. Affiliated tissues include liver and small intestine, and related mouse phenotypes are Increased shRNA abundance (Z-score > 2) and neoplasm.

Genetics Home Reference:25 Cholangiocarcinoma is a group of cancers that begin in the bile ducts. Bile ducts are branched tubes that connect the liver and gallbladder to the small intestine. They carry bile, which is a fluid that helps the body digest the fats in food. Bile is produced in the liver and stored in the gallbladder before being released in the small intestine after a person eats.

Disease Ontology:11 A bile duct adenocarcinoma that has material basis in bile duct epithelial cells.

Related Diseases for Cholangiocarcinoma, Susceptibility to

About this section

Diseases related to Cholangiocarcinoma, Susceptibility to via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 317)
idRelated DiseaseScoreTop Affiliating Genes
1klatskin's tumor32.8AFP, KRT20, KRT7
2colorectal cancer27.5CDH1, CDX2, ERBB2, KRT19, KRT20, KRT7
3intrahepatic cholangiocarcinoma12.4
4hilar cholangiocellular carcinoma12.1
5sarcomatous intrahepatic cholangiocarcinoma11.9
6mucinous intrahepatic cholangiocarcinoma11.8
7signet ring cell intrahepatic cholangiocarcinoma11.8
8contractural arachnodactyly, congenital11.7
9clonorchiasis11.3
10opisthorchiasis11.2
11bile duct carcinoma11.1
12central cord syndrome11.0
13familial calcium pyrophosphate deposition11.0
14pigment dispersion syndrome10.9
15congenitally corrected transposition of the great arteries10.8
16cholangitis, primary sclerosing10.8
17hepatitis10.4
18hepatocellular carcinoma10.4
19cholangitis10.4
20sclerosing cholangitis10.4
21split-hand with obstructive uropathy, spina bifida, and diaphragmatic defects10.3GPC3, KRT20
22lethal congenital contracture syndrome10.3AFP, CDX2, MUC1
23clitoris cancer10.3CDX2, KRT20, MUC1
24cervix endometriosis10.3CDX2, KRT20, MUC2
25small intestine carcinoid neuroendocrine tumor10.3KRT20, MUC1, MUC2
26mesenchymoma10.3CDX2, KRT20, MUC1
27placental site trophoblastic tumor10.3KRT20, MUC1, MUC2
28chondroblastoma10.3GPC3, KRT20, MUC1
29adult central nervous system immature teratoma10.3ERBB2, MCL1
30neuroendocrine tumor10.3CDX2, KRT20, PTGS2
31neuroretinitis10.3CDX2, KRT20, MUC2
32substance abuse10.3CDH1, ERBB2, MUC1
33fallopian tube leiomyosarcoma10.3CDH1, MUC1, MUC2
34renal infectious disease10.3ERBB2, KRT8
35neurofibrosarcoma10.3CDX2, KRT20, MUC1, MUC2
36pelvic inflammatory disease10.3CDX2, KRT20, MUC1, MUC2
37tabes dorsalis10.2CDX2, KRT20, MUC1, MUC2
38allergic contact dermatitis10.2CDX2, KRT20, MUC1, MUC2
39ideomotor apraxia10.2CDH1, CDX2, PTGS2
40acquired hemangioma10.2CDX2, ERBB2, PTGS2
41large cell neuroendocrine carcinoma10.2CDX2, KRT20, KRT8
42focal epithelial hyperplasia10.2AFP, CDX2, GPC3
43cranial nerve disease10.2AFP, KRT20, NCAM1
44radiculopathy10.2KRT20, KRT7
45gastrointestinal system cancer10.2CDH1, ERBB2, MUC1, MUC2
46scirrhous adenocarcinoma10.2CDH1, KRT8, MUC1
47infiltrative basal cell carcinoma10.2CDH1, KRT19, KRT20
48adult myxoid chondrosarcoma10.2KRT20, KRT7
49thymic dysplasia10.2MUC1, NCAM1
50dissociative amnesia10.2KRT19, KRT8

Graphical network of the top 20 diseases related to Cholangiocarcinoma, Susceptibility to:



Diseases related to cholangiocarcinoma, susceptibility to

Symptoms & Phenotypes for Cholangiocarcinoma, Susceptibility to

About this section


Clinical features from OMIM:

615619

Human phenotypes related to Cholangiocarcinoma, Susceptibility to:

 54 64 (show all 9)
id Description HPO Frequency Orphanet Frequency HPO Source Accession
1 jaundice64 54 Very frequent (99-80%) HP:0000952
2 pruritus64 54 Frequent (79-30%) HP:0000989
3 fever64 54 Occasional (29-5%) HP:0001945
4 abdominal pain64 54 Occasional (29-5%) HP:0002027
5 anorexia64 54 Occasional (29-5%) HP:0002039
6 acholic stools64 54 Very frequent (99-80%) HP:0011985
7 fatigue64 54 Frequent (79-30%) HP:0012378
8 biliary tract neoplasm64 54 Very frequent (99-80%) HP:0100574
9 cholangiocarcinoma64 HP:0030153

UMLS symptoms related to Cholangiocarcinoma, Susceptibility to:


abdominal pain, malaise, constipation, diarrhea, dyspepsia, heartburn, icterus, nausea and vomiting, gastrointestinal gas

GenomeRNAi Phenotypes related to Cholangiocarcinoma, Susceptibility to according to GeneCards Suite gene sharing:

26
idDescriptionGenomeRNAi Source AccessionScoreTop Affiliating Genes
1GR00366-A-1929.4AFP, KRT7, KRT8

MGI Mouse Phenotypes related to Cholangiocarcinoma, Susceptibility to according to GeneCards Suite gene sharing:

41
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00020068.6AFP, ASPH, CDH1, CDX2, ERBB2, KRT19
2MP:00053808.3CDH1, CDX2, ERBB2, GPC3, KRT19, KRT8
3MP:00053798.3AFP, CDH1, CDX2, ERBB2, KRT19, MCL1
4MP:00053898.2AFP, ASPH, CDH1, CDX2, ERBB2, GPC3
5MP:00053857.5ASPH, CDH1, CDX2, ERBB2, GPC3, KRT19
6MP:00053847.4CDH1, CDX2, ERBB2, GPC3, KRT19, KRT7
7MP:00053817.2ASPH, CDH1, CDX2, ERBB2, GPC3, KRT19
8MP:00053766.8AFP, ASPH, CDH1, CDX2, ERBB2, GPC3
9MP:00107686.8AFP, ASPH, CDH1, CDX2, ERBB2, GPC3

Drugs & Therapeutics for Cholangiocarcinoma, Susceptibility to

About this section

Drugs for Cholangiocarcinoma, Susceptibility to (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 232)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
EtomidateapprovedPhase 46533125-97-236339, 667484
Synonyms:
(+)-Ethyl 1-(alpha-methylbenzyl)imidazole-5-carboxylate
(+)-Etomidate
(+)-ethyl 1-(α-methylbenzyl)imidazole-5-carboxylate
(+)-etomidate
(R)-(+)-1-(alpha-Methylbenzyl)imidazole-5-carboxylic acid ethyl ester
(R)-1-(1-phenylethyl)-1H-imidazole-5-carboxylic acid ethyl ester
(d)-Etomidate
1-(1-Phenylethyl)-1H-imidazole-5-carboxylic acid ethyl ester
1-(1-Phenylethyl)-imidazole-5-carboxylic acid, ethyl ester
1-(alpha-Methylbenzyl)-1H-imidazole-5-carboxylic acid ethyl ester
15301-65-2
1H-Imidazole-5-carboxylic acid, 1-((1R)-1-phenylethyl)-, ethyl ester
3-((R)-1-Phenyl-ethyl)-3H-imidazole-4-carboxylic acid ethyl ester
3-(1-Phenyl-ethyl)-3H-imidazole-4-carboxylic acid ethyl ester
33125-97-2
AC-5898
AC1L1VLF
AC1Q34BV
AC1Q64LP
AKOS000548952
Absele
Amidate
Amidate (TN)
Amidate (pharmaceutical)
Amidate, Etomidate
BAS 01947657
BRN 0665833
C07522
C14H16N2O2
CHEBI:129025
CHEMBL23731
CID36339
CPD000010931
D-Etomidate
D005045
D00548
 
DB00292
EINECS 251-385-9
Ethnor
Ethomidate
Ethyl 1-(1-phenylethyl)-1H-imidazole-5-carboxylate
Etomidate
Etomidate (USAN/INN)
Etomidate [USAN:BAN:INN]
Etomidato
Etomidato [INN-Spanish]
Etomidatum
Etomidatum [INN-Latin]
Etomidic acid
HMS1571A04
HMS1612G10
HMS2093P17
Hypnomidate
LS-78232
MLS000034952
MLS001240191
MolPort-000-917-569
Prestwick0_001041
Prestwick1_001041
Prestwick2_001041
R 16659
R 26490
R-(+)-Ethyl 1-(1-phenylethyl)-1H-imidazole-5-carboxylate
R-26490
R26490
Radenarcon
Radenarkon
S1329_Selleck
SAM002548930
SBB066197
SMR000010931
SPBio_002901
UNII-Z22628B598
ethyl 3-(1-phenylethyl)imidazole-4-carboxylate
2
MeperidineapprovedPhase 47557-42-14058
Synonyms:
1-Methyl-4-phenyl-4-piperidinecarboxylic acid ethyl ester
1-Methyl-4-phenyl-piperidin-4-carbon-saeure-aethylester
1-Methyl-4-phenyl-piperidin-4-carbon-saeure-aethylester [German]
1-Methyl-4-phenylisonipecotic acid, ethyl ester
1-Methyl-4-phenylpiperidine-4-carboxylic acid ethyl ester
4-Carbethoxy-1-methyl-4-phenylpiperidine
4-Piperidinecarboxylic acid, 1-methyl-4-phenyl-, ethyl ester
50-13-5 (hydrochloride)
57-42-1
610593_ALDRICH
610593_FLUKA
AC1L1HBJ
C07128
CHEBI:122528
CHEMBL607
CID4058
D008614
D08343
DB00454
DEA No. 9230
Demarol
Demerol
DivK1c_000983
Dolcontral
Dolosal
Dolsin
EINECS 200-329-1
Ethyl 1-methyl-4-phenylisonipecotate
Ethyl 1-methyl-4-phenylpiperidine-4-carboxylate
HSDB 3116
IDI1_000983
Isonipecain
Isonipecaine
Isonipecaïne
Isonipecotic acid, 1-methyl-4-phenyl-, ethyl ester
KBio1_000983
 
L000908
LS-85121
Lidol
Lydol
Meperidine
Meperidine solution
Meperidol
Methyl phenylpiperidine carbonic acid ethyl ester
MolPort-001-785-564
N-Methyl-4-phenyl-4-carbethoxypiperidine
NINDS_000983
Nemerol
Operidine EPJ I
Operidine EPJ-I
Pethanol
Pethidin
Pethidine
Pethidine (INN)
Pethidine DBL
Pethidine DBL (TN)
Pethidine dbl
Pethidineter
Pethidinum
Pethidinum [INN-Latin]
Petidina
Petidina [INN-Spanish]
Petydyna
Petydyna [Polish]
Phetidine
Piperosal
Pipersal
Péthidine
Sauteralgyl
Spasmedal
Spasmodolin
UNII-9E338QE28F
YIsonipecotic acid, 1-methyl-4-phenyl-, ethyl ester (8CI)
meperidine
3
Midazolamapproved, illicitPhase 472359467-70-84192
Synonyms:
4H-Imidazo[1,5-a][1,4]benzodiazepine, 8-chloro-6-(2-fluoro-phenyl)-1-methyl-, (Z)-2-butenedioate
59467-70-8
8-Chlor-6-(2-fluorphenyl)-1-methyl-4H-imidazo(1,5-a)(1,4)benzodiazepin
8-Chloro-6-(2-fluorophenyl)-1-methyl-4H-imidazo[1,5-a][1,4]benzodiazepine
8-Chloro-6-(2-fluorophenyl)-1-methyl-4H-imidazo[1,5a][1,4]benzodiazepine hydrochloride
8-Chloro-6-(O-fluorophenyl)-1-methyl-4H-imidazo[1,5-a][1,4]-benzodiazepine
8-Chloro-6-(o-fluorophenyl)-1-methyl-4H-imidazo(1,5-a)(1,4)benzodiazepine
AC-18749
AC1L1HMA
BIDD:GT0647
BRN 0625572
Buccolam
C07524
C18H13ClFN3
CHEMBL655
CID4192
D00550
DB00683
DEA No. 2884
Dazolam
Dea No. 2884
 
Dormicum
Dormicum (TN)
EINECS 261-774-5
LS-77780
Midanium
Midazolam
Midazolam (JAN/INN)
Midazolam Base
Midazolam Hcl
Midazolam [INN:BAN:JAN]
Midazolamum
Midazolamum [INN-Latin]
Midosed
MolPort-003-849-219
NCGC00168254-01
Ro 21-3981
TL8003787
UC429_SIGMA
UNII-R60L0SM5BC
Versed
ZINC00001732
midazolam
nchembio747-comp32
4
DesfluraneapprovedPhase 415057041-67-542113
Synonyms:
(+-)-2-Difluoromethyl 1,2,2,2-tetrafluoroethyl ether
1,1,1,2-Tetrafluoro-2-(difluoromethoxy)ethane
1,1,1,2-tetrafluoro-2-(difluoromethoxy)ethane
2-(difluoromethoxy)-1,1,1,2-tetrafluoroethane
57041-67-5
AC1L274J
AC1Q4ICY
C07519
C3H2F6O
CHEBI:4445
CHEMBL1200733
CID42113
D00546
DB01189
DESFLURANE
Desflurane
 
Desflurane (JAN/USP/INN)
Desflurane [USAN:INN]
Desflurano
Desflurano [INN-Spanish]
Desfluranum
Desfluranum [INN-Latin]
Difluoromethyl 1,2,2,2-tetrafluoroethyl ether
I 653
I-653
I653
LS-65505
MolPort-001-776-387
PC6781E
Suprane
Suprane (TN)
UNII-CRS35BZ94Q
difluoromethyl 1,2,2,2-tetrafluoroethyl ether
r-e 236ea1
5
Sevofluraneapproved, vet_approvedPhase 450828523-86-65206
Synonyms:
1,1,1,3,3,3-Hexafluoro-2-(fluoromethoxy)propane
28523-86-6
AC-15484
AC1L1JU0
BRN 2041023
Bax 3084
C009250
C07520
C4H3F7O
CHEBI:9130
CHEMBL1200694
CID5206
D00547
DB01236
F0691
Fluoromethyl 1,1,1,3,3,3-Hexafluoroisopropyl Ether
Fluoromethyl 2,2,2-trifluoro-1-(trifluoromethyl)ethyl ether
I14-13357
LS-67851
MR6S4
 
MR_6S4
MolPort-001-775-746
NCGC00167421-01
PC4681
Sevofluran
Sevoflurane
Sevoflurane (JAN/USAN/INN)
Sevoflurane [USAN:INN:BAN:JAN]
Sevoflurano
Sevoflurano [INN-Spanish]
Sevofluranum
Sevofluranum [INN-Latin]
Sevofrane
Sevorane
Sojourn
UNII-38LVP0K73A
Ultane
Ultane (TN)
ZINC01530810
fluoromethyl hexafluoroisopropyl ether
fluoromethyl-2,2,2-trifluoro-1-(trifluoromethyl)ethyl ether
sevoflurane
6
Isofluraneapproved, vet_approvedPhase 417126675-46-73763
Synonyms:
1-Chloro-2,2,2-trifluoroethyl difluoromethyl ether
1-chloro-2,2,2-Trifluoroethyl difluoromethyl ether
2-Chloro-2-(difluoromethoxy)-1,1,1-trifluoroethane
2-chloro-2-difluoromethoxy-1,1,1-trifluoroethane
26675-46-7
AC-154802
AC1L1GNN
AErrane (Veterinary)
Aerrane
BRN 1852087
C07518
CCRIS 3043
CHEBI:6015
CHEMBL1256
CID3763
Compound 469
D00545
D007530
DB00753
EINECS 247-897-7
Ethane
Ether, 1-chloro-2,2,2-trifluoroethyl difluoromethyl
 
Forane
Forane (TN)
Forene
I14-1303
IsoFlo
Isoflurane
Isoflurane (JP15/USP/INN)
Isoflurane [Anaesthetics, volatile]
Isoflurane [USAN:BAN:INN:JAN]
Isoflurane [USAN:INN:BAN:JAN]
Isoflurane [Usan:Ban:Inn:Jan]
Isoflurano
Isoflurano [INN-Spanish]
Isofluranum
Isofluranum [INN-Latin]
Jsp005223
LS-7462
MolPort-000-153-606
NCGC00181037-01
R-E 235dal
ST51041445
UNII-CYS9AKD70P
isoflurane
7HematinicsPhase 4, Phase 3, Phase 1, Phase 21684
8
BilirubinPhase 4116635-65-45280352
Synonyms:
(4Z,15Z)-Bilirubin IXa
(Z,Z)-Bilirubin IXa
1,10,19,22,23,24-Hexahydro-2,7,13,17-tetramethyl-1,19-dioxo-3,18-divinyl-Biline-8,12-dipropionate
1,10,19,22,23,24-Hexahydro-2,7,13,17-tetramethyl-1,19-dioxo-3,18-divinyl-Biline-8,12-dipropionic acid
2,17-Diethenyl-1,10,19,22,23,24-hexahydro-3,7,13,18-tetramethyl-1,19-dioxo-21H-Biline-8,12-dipropanoate
2,17-Diethenyl-1,10,19,22,23,24-hexahydro-3,7,13,18-tetramethyl-1,19-dioxo-21H-Biline-8,12-dipropanoic acid
3-(2-((3-(2-Carboxyethyl)-4-methyl-5-((3-methyl-5-oxo-4-vinyl-1,5-dihydro-2H-pyrrol-2-ylidene)methyl)-1H-pyrrol-2-yl)methyl)-4-methyl-5-((4-methyl-5-oxo-3-vinyl-1,5-dihydro-2H-pyrrol-2-ylidene)methyl)-1H-pyrrol-3-yl)propanoate
3-(2-((3-(2-Carboxyethyl)-4-methyl-5-((3-methyl-5-oxo-4-vinyl-1,5-dihydro-2H-pyrrol-2-ylidene)methyl)-1H-pyrrol-2-yl)methyl)-4-methyl-5-((4-methyl-5-oxo-3-vinyl-1,5-dihydro-2H-pyrrol-2-ylidene)methyl)-1H-pyrrol-3-yl)propanoic acid
 
3-(2-((3-(2-Carboxyethyl)-4-methyl-5-[(Z)-(3-methyl-5-oxo-4-vinyl-1,5-dihydro-2H-pyrrol-2-ylidene)methyl]-1H-pyrrol-2-yl)methyl)-4-methyl-5-[(Z)-(4-methyl-5-oxo-3-vinyl-1,5-dihydro-2H-pyrrol-2-ylidene
3-[2-[[3-(2-Carboxyethyl)-5-[(3-ethenyl-4-methyl-5-oxo-pyrrol-2-ylidene)methyl]-4-methyl-1H-pyrrol-2-yl]methyl]-5-[(4-ethenyl-3-methyl-5-oxo-pyrrol-2-ylidene)methyl]-4-methyl-1H-pyrrol-3-yl]propanoate
3-[2-[[3-(2-Carboxyethyl)-5-[(3-ethenyl-4-methyl-5-oxo-pyrrol-2-ylidene)methyl]-4-methyl-1H-pyrrol-2-yl]methyl]-5-[(4-ethenyl-3-methyl-5-oxo-pyrrol-2-ylidene)methyl]-4-methyl-1H-pyrrol-3-yl]propanoic acid
3-[2-[[3-(2-Carboxyethyl)-5-[(Z)-(3-ethenyl-4-methyl-5-oxo-pyrrol-2-ylidene)methyl]-4-methyl-1H-pyrrol-2-yl]methyl]-5-[(Z)-(4-ethenyl-3-methyl-5-oxo-pyrrol-2-ylidene)methyl]-4-methyl-1H-pyrrol-3-yl]propanoate
3-[2-[[3-(2-Carboxyethyl)-5-[(Z)-(3-ethenyl-4-methyl-5-oxo-pyrrol-2-ylidene)methyl]-4-methyl-1H-pyrrol-2-yl]methyl]-5-[(Z)-(4-ethenyl-3-methyl-5-oxo-pyrrol-2-ylidene)methyl]-4-methyl-1H-pyrrol-3-yl]propanoic acid
Bilirubin
Bilirubin IX-alpha
Cholerythrin
Hematoidin
9Liver ExtractsPhase 4, Phase 2, Phase 3, Phase 14067
10
BismuthPhase 4, Phase 31407440-69-916682734, 105143
Synonyms:
17034_FLUKA
24267-48-9
25243-76-9
264008_ALDRICH
265462_ALDRICH
265470_ALDRICH
452386_ALDRICH
556130_ALDRICH
7440-69-9
83Bi
95372_ALDRICH
95372_FLUKA
95375_FLUKA
AC1NSDYX
AC1O4PN8
AR-1I0647
BISMUTH, 99.95%
 
BISMUTH, 99.999%
Bi
Bismut
Bismuth standard for AAS
Bismuth standard for ICP
Bismuth(III) nitrate solution
Bismuth, elemental
Bismuth-209
C15471
CHEBI:33301
CID5359367
EINECS 231-177-4
HSDB 2078
LS-44708
LTBB002773
MolPort-003-925-759
Wismut
bismuth
bismuto
11Tranquilizing AgentsPhase 44265
12Psychotropic DrugsPhase 46430
13Peripheral Nervous System AgentsPhase 4, Phase 3, Phase 2, Phase 123689
14Anti-Anxiety AgentsPhase 41885
15AnestheticsPhase 49596
16Central Nervous System DepressantsPhase 413403
17Anesthetics, IntravenousPhase 42538
18Neurotransmitter AgentsPhase 4, Phase 218340
19Anesthetics, GeneralPhase 42934
20GABA AgentsPhase 41684
21Analgesics, OpioidPhase 43238
22NarcoticsPhase 43646
23GABA ModulatorsPhase 4904
24Hypnotics and SedativesPhase 42616
25AnalgesicsPhase 4, Phase 1, Phase 211733
26Adjuvants, AnesthesiaPhase 41674
27Anesthetics, InhalationPhase 4684
28Platelet Aggregation InhibitorsPhase 42516
29Omega 3 Fatty AcidNutraceuticalPhase 41018
30
TrioxsalenapprovedPhase 2, Phase 3413902-71-45585
Synonyms:
2',4,8-Trimethylpsoralen
4,5',8-Trimethylpsoralen
4,8,5'-Trimethylpsoralen
6-Hydroxy-beta,2,7-trimethyl-5-benzofuranacrylic acid, delta-lactone
Trimethylpsoralen
Trioxisaleno
 
Trioxsalen
Trioxysalen
Trioxysalene
Trioxysalenum
Trisoralen
trimethylpsoralen
trioxysalen
trisoralen
31
FluorouracilapprovedPhase 3, Phase 2, Phase 1185651-21-83385
Synonyms:
1-fluoro-1h-pyrimidine-2,4-dione
1004-03-1
1upf
2,4-Dihydroxy-5-fluoropyrimidine
2,4-Dioxo-5-fluoropryimidine
2,4-Dioxo-5-fluoropyrimidine
47576_FLUKA
4921-97-5
5 FU Lederle
5 FU medac
5 Fluorouracil
5 Fluorouracil biosyn
5 HU Hexal
5-FU
5-FU (TN)
5-FU Lederle
5-FU medac
5-Faracil
5-Fluor-2,4(1H,3H)-pyrimidindion
5-Fluor-2,4(1H,3H)-pyrimidindion [Czech]
5-Fluor-2,4-dihydroxypyrimidin
5-Fluor-2,4-dihydroxypyrimidin [Czech]
5-Fluor-2,4-pyrimidindiol
5-Fluor-2,4-pyrimidindiol [Czech]
5-Fluoracil
5-Fluoracil [German]
5-Fluoracyl
5-Fluoro-2,4(1H,3H)-pyrimidinedione
5-Fluoro-2,4-pyrimidinedione
5-Fluoropyrimidin-2,4-diol
5-Fluoropyrimidine-2,4-dione
5-Fluorouracil
5-Fluorouracil-biosyn
5-Fluoruracil
5-Fluoruracil [German]
5-Fluracil
5-Ftouracyl
5-HU Hexal
5-fluoro uracil
5-fluoro-1H-pyrimidine-2,4-dione
5-fluoropyrimidine-2,4(1H,3H)-dione
5-fluorouracil
51-21-8
5FU
79108-01-3
AC-11201
AC1L1FTE
AC1Q4N2X
AI3-25297
AKOS000119162
AKOS003237897
AccuSite
Actino-Hermal
Adrucil
Adrucil (TN)
Allergan Brand of Fluorouracil
Arumel
BB_NC-0576
BSPBio_002048
C07649
C4H3FN2O2
CCRIS 2582
CHEBI:46345
CHEMBL185
CID3385
CPD0-1327
CPD000038082
CSP Brand of Fluorouracil
Carac
Carac (TN)
Carzonal
Cinco FU
Cytosafe
D005472
D00584
DB00544
Dakota Brand of Fluorouracil
Dakota, Fluorouracile
Dermatech Brand of Fluorouracil
Dermik Brand of Fluorouracil
DivK1c_000054
EINECS 200-085-6
EU-0100536
Effluderm
Effluderm (free base)
Efudex
Efudix
Efurix
F 6627
F0151
F6627_SIGMA
F8423_SIGMA
FT-0082524
FU
Ferrer Brand of Fluorouracil
Fiverocil
Fluoro Uracil
Fluoro Uracile ICN
Fluoro-Uracile ICN
Fluoro-uracile
Fluoro-uracilo
Fluoroblastin
Fluoroplex
Fluoroplex (TN)
Fluorouracil
Fluorouracil (JP15/USP/INN)
Fluorouracil GRY
Fluorouracil Mononitrate
Fluorouracil Monopotassium Salt
Fluorouracil Monosodium Salt
Fluorouracil Potassium Salt
Fluorouracil Teva Brand
Fluorouracil [USAN:INN:BAN:JAN]
 
Fluorouracil-GRY
Fluorouracile
Fluorouracile Dakota
Fluorouracile [DCIT]
Fluorouracilo
Fluorouracilo Ferrer Far
Fluorouracilo [INN-Spanish]
Fluorouracilum
Fluorouracilum [INN-Latin]
Fluoruracil
Fluouracil
Flurablastin
Fluracedyl
Fluracil
Fluracilum
Fluri
Fluril
Fluro Uracil
Fluroblastin
Flurodex
Flurouracil
Flurox
Ftoruracil
Gry Brand of Fluorouracil
HMS1920O18
HMS2090I04
HMS2091F19
HMS500C16
HSDB 3228
Haemato Brand of Fluorouracil
Haemato fu
Haemato-fu
Hexal Brand of Fluorouracil
I07-0022
ICN Brand of Fluorouracil
IDI1_000054
IN1335
KBio1_000054
KBio2_001321
KBio2_003889
KBio2_006457
KBio3_001268
KBioGR_001253
KBioSS_001321
Kecimeton
LS-153
Lopac-F-6627
Lopac0_000536
MLS000069498
MLS002415705
MolPort-000-156-102
MolPort-003-990-447
MolPort-004-758-143
MolPort-004-758-144
MolPort-005-861-486
NCGC00015442-01
NCGC00015442-03
NCGC00015442-10
NCGC00091349-01
NCGC00091349-02
NCGC00091349-03
NCGC00091349-04
NCGC00091349-05
NCGC00091349-07
NCGC00091349-08
NCI60_001652
NINDS_000054
NSC 19893
NSC-19893
NSC19893
Neocorp Brand of Fluorouracil
Neofluor
Onkofluor
Onkoworks Brand of Fluorouracil
Phthoruracil
Phtoruracil
Queroplex
Ribofluor
Riemser Brand of Fluorouracil
Ro 2-9757
Ro-2-9757
Roche Brand of Fluorouracil
S1209_Selleck
SAM002264615
SMR000038082
SPBio_000291
SPECTRUM1500305
STK297802
Spectrum2_000076
Spectrum3_000434
Spectrum4_000557
Spectrum5_000718
Spectrum_000841
T5233394
TL8006093
Teva Brand of Fluorouracil
Timazin
U 8953
U-8953
UNII-U3P01618RT
UPCMLD-DP130
UPCMLD-DP130:001
URF
Ulup
WLN: T6MVMVJ EF
ZINC00897110
biosyn Brand of Fluorouracil
fluorouracil
inhibits thymilidate synthetase
medac Brand of Fluorouracil
nchembio.90-comp3
nchembio809-comp6
ribosepharm Brand of Fluorouracil
tetratogen
32
CisplatinapprovedPhase 3, Phase 2, Phase 1277015663-27-184093, 441203, 2767
Synonyms:
(SP-4-1)-diamminedichloridoplatinum
(SP-4-1)-diamminedichloroplatinum
(SP-4-2)-diamminedichloridoplatinum
(SP-4-2)-diamminedichloroplatinum
Abiplatin
Biocisplatinum
Briplatin
CACP
CDDP
CHEBI:35852
CID441203
CPD0-1392
CPDC
CPDD
Carboquone
Cis Pt II
Cis-DDP
Cis-Diaminedichloroplatinum
Cis-Diamminedichloroplatinum
Cismaplat
Cisplatine
Cisplatino
Cisplatinum
Cisplatyl
Citoplationo
DB00515
DDP
DDPT
Diamminedichloroplatinum
 
EU-0100918
Lederplatin
Neoplatin
Peyrone's chloride
Peyrone's salt
Plastin
Platamine
Platiblastin
Platidiam
Platinex
Platinol
Platinol-AQ
Platinoxan
Platinum Ammine Chloride
Platinum Ammonium Chloride
Platinum Diamine Dichloride
Randa
Trans-DDP
Trans-Diaminedichloroplatinum
Trans-Diamminedichloroplatinum
Trans-Dichlorodiammine Platinum
Trans-Platinumdiammine Dichloride
cis-DDP
cis-Diamminedichloroplatinum
cis-Dichlorodiammineplatinum(II)
cis-[PtCl2(NH3)2]
cis-diamminedichloridoplatinum(II)
cis-diamminedichloroplatinum(II)
nchembio773-comp1
trans-diamminedichloridoplatinum(II)
33
Capecitabineapproved, investigationalPhase 3, Phase 2, Phase 11342154361-50-960953
Synonyms:
(1-(5-Deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamic acid pentyl ester
154361-50-9
158798-73-3
5'-Deoxy-5-fluoro-N-((pentyloxy)carbonyl)cytidine
5'-deoxy-5-fluoro-N-[(pentyloxy)carbonyl]cytidine
AC1L1U83
AC1Q4KU8
Ambap154361-50-9
C110904
C12650
C15H22FN3O6
CAPE
CAPECITABINE
CHEBI:31348
CHEMBL1773
CID60953
Capecitabin
Capecitabina
Capecitabine (JAN/USAN/INN)
Capecitabine [USAN]
Capecitabinum
Capecitibine
Capiibine
Carbamic acid, (1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-, pentyl ester
Caxeta
 
D01223
DB01101
FT-0082472
HSDB 7656
LS-59070
MolPort-005-938-254
N(4)-Pentyloxycarbonyl-5'-deoxy-5-fluorocytidine
Pentyl 1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamate
Pentyl [1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamate
R-340
R340
RG-340
Ro 09-1978
Ro 09-1978/000
Ro-09-1978
Ro-09-1978/000
S1156_Selleck
UNII-6804DJ8Z9U
Xabine
Xeloda
Xeloda (TN)
Xeloda, Captabin, Capecitabine
ZINC03806413
capecitabina
capecitabine
capecitabinum
pentyl N-[1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-methyloxolan-2-yl]-5-fluoro-2-oxopyrimidin-4-yl]carbamate
34
GemcitabineapprovedPhase 3, Phase 2, Phase 1201895058-81-460750
Synonyms:
103882-84-4
122111-03-9
2',2'-DiF-dC
2',2'-Difluoro-2'-deoxycytidine
2',2'-Difluorodeoxycytidine
2'-Deoxy-.beta.-D-2',2'-difluorocytidine
2'-Deoxy-2',2'-difluorocytidine
4-Amino-1-[(2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one
4-Amino-1-[3,3-difluoro-4-hydroxy-5-(hydroxymethyl) tetrahydrofuran-2-yl]-1H-pyrimidin-2-one
4-amino-1-((2R,4R,5R)-3,3-Difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
95058-81-4
AB1004842
AC1L1TUQ
C07650
CCRIS 8984
CHEBI:175901
CHEMBL888
CID60750
Cytidine, 2'-deoxy-2',2'-difluoro-2'-Deoxy-.beta.-D-2',2'-difluorocytidine
D02368
DB00441
DDFC
DFDC
DFdC
DFdCyd
Folfugem
GEO
Gamcitabine
GemLip
Gemcel
 
Gemcin
Gemcitabin
Gemcitabina
Gemcitabina [INN-Spanish]
Gemcitabine
Gemcitabine (USAN/INN)
Gemcitabine HCl
Gemcitabine hydrochloride
Gemcitabine stereoisomer
Gemcitabinum
Gemcitabinum [INN-Latin]
Gemtro
Gemzar
Gemzar (hydrochloride)
HMS2089P10
HSDB 7567
Inno-D07001
LS-59139
LY 188011
LY-188011
LY188011
NCGC00168784-01
NChemBio.2007.10-comp25
NSC 613327
NSC613327
TL8005979
UNII-B76N6SBZ8R
ZINC18279854
Zefei
gemcitabine
nchembio.573-comp7
nchembio.90-comp2
35
MelphalanapprovedPhase 2, Phase 3729148-82-34053, 460612
Synonyms:
(2S)-2-amino-3-[4-[bis(2-chloroethyl)amino]phenyl]propanoic acid
(2s)-2-amino-3-(4-[bis(2-chloroethyl)amino]phenyl)propanoic acid
148-82-3
3-(P-(Bis(2-chloroethyl)amino)phenyl)-L-alanine
3-(p-(Bis(2-chloroethyl)amino)phenyl)-L-alanine
3-(p-(Bis(2-chloroethyl)amino)phenyl)alanine
3-P-(Di(2-chloroethyl)amino)-phenyl-L-alanine
3-p-(Di(2-chloroethyl)amino)-phenyl-L-alanine
3025 C.B.
3025 c.b
3223-07-2
4-(Bis(2-chloroethyl)amino)-L-phenylalanine
4-14-00-01689 (Beilstein Handbook Reference)
4-[Bis(2-chloroethyl)amino]-L-phenylalanine
4-[Bis-(2-chloroethyl)amino]-L-phenylalanine
AC1LA2OE
ALKERAN (TN)
AY3360000
Alanine Nitrogen Mustard
Alkeran
AmbotzHAA1563
At-290
BIDD:GT0044
BRD-K87827419-001-02-8
BRN 2816456
BSPBio_002407
C13H18Cl2N2O2
CB 3025
CB-3025
CCRIS 374
CHEBI:165415
CHEBI:28876
CHEMBL852
CID460612
D00369
DivK1c_000653
EINECS 205-726-3
HMS2090B09
HMS2091B16
HMS502A15
HSDB 3234
IDI1_000653
KBio1_000653
KBio2_000877
KBio2_003445
KBio2_006013
KBio3_001627
KBioGR_001284
KBioSS_000877
L-3-(P-(Bis(2-chloroethyl)amino)phenyl)alanine
L-3-(p-(Bis(2-chloroethyl)amino)phenyl)alanine
L-3-(para-(Bis(2-chloroethyl)amino)phenyl)alanine
L-PAM
L-Phenylalanine mustard
L-Sarcolysin
L-Sarcolysine
L-Sarkolysin
LS-15868
LS-865
 
Levofalan
Levofolan
Levopholan
M2011_SIGMA
MELPHALAN (SEE ALSO TRANSGENIC MODEL EVALUATION (MELPHALAN))
MLS001333666
MLS002153368
Melfalan
Melfalano
Melfalano [INN-Spanish]
Melphalan (JP15/USP/INN)
Melphalan [USAN:INN:BAN:JAN]
Melphalanum
Melphalanum [INN-Latin]
Mephalan
MolPort-003-665-535
NCGC00090757-01
NCGC00090757-02
NCGC00090757-03
NCI-C04853
NINDS_000653
NIOSH/AY3360000
NSC 241286
NSC 8806
NSC-8806
NSC241286
NSC8806
P-Di-(2-chloroethyl)amino-L-phenylalanine
P-L-Sarcolysin
P-N-Bis(2-chloroethyl)amino-L-phenylalanine
Phenylalanine mustard
Phenylalanine nitrogen mustard
Prestwick_1006
RCRA waste no. U150
Rcra waste number U150
SK-15673
SMP2_000174
SMR000058720
SPBio_000287
SPECTRUM1500382
Sarcolysine
Sarkolysin
Spectrum2_000074
Spectrum3_000684
Spectrum4_000882
Spectrum5_001601
Spectrum_000397
TL8001065
TRANSGENIC LEP (MELPHALAN) (SEE ALSO MELPHALAN)
TRANSGENIC MODEL EVALUATION (MELPHALAN)
UNII-Q41OR9510P
melphalan
p-Bis(beta-chloroethyl)aminophenylalanine
p-Di-(2-chloroethyl)amino-L-phenylalanine
p-L-Sarcolysin
p-L-sarcolysine
p-N,N-bis(2-chloroethyl)amino-L-phenylalanine
p-N-Bis(2-chloroethyl)amino-L-phenylalanine
p-N-Di(chloroethyl)aminophenylalanine
p-N-di(chloroethyl)aminophenylala nine
phenylalanine nitrogen mu stard
36
Oxaliplatinapproved, investigationalPhase 3, Phase 2, Phase 1146061825-94-35310940, 9887054, 6857599, 9887054, 43805
Synonyms:
CHEMBL1201055
CID9887054
D01790
DACPLAT
Diaminocyclohexane Oxalatoplatinum
Eloxatin
Eloxatin (TN)
Elplat
Foloxatine
L-OHP
Oxalatoplatin
 
Oxalatoplatinum
Oxaliplatin (JAN/USAN/INN)
Oxaliplatin [Usan:Inn:Ban]
Oxaliplatino [Spanish]
Oxaliplatinum [Latin]
Oxaloplatine [French]
Oxaloplatino [Spanish]
Transplatin
oxaliplatin
oxaliplatine
oxaliplatino
oxaliplatinum
37
LevoleucovorinapprovedPhase 3, Phase 2, Phase 172868538-85-2
Synonyms:
(6S)-5-Formyl-5,6,7,8-tetrahydrofolic acid
(6S)-5-formyltetrahydrofolic acid
(6S)-Folinic acid
(6S)-Leucovorin
 
(S)-Leucovorin
Citrovorum factor
L-Folinic acid
Levofolene
Levofolinic acid
N-[4-({[(6S)-2-amino-5-formyl-4-oxo-1,4,5,6,7,8-hexahydropteridin-6-yl]methyl}amino)benzoyl]-L-glutamic acid
38
Ursodeoxycholic acidapproved, investigationalPhase 2, Phase 397128-13-231401
Synonyms:
(3a,5b,7b)-3,7-dihydroxy-cholan-24-oate
(3a,5b,7b)-3,7-dihydroxy-cholan-24-oic acid
(3a,5b,7b)-3,7-dihydroxycholan-24-oic acid
(3alpha,5beta,7beta)-3,7-dihydroxycholan-24-oic acid
(3alpha,5beta,7beta,8xi)-3,7-dihydroxycholan-24-oic acid
(3α,5β,7β)-3,7-dihydroxycholan-24-oic acid
(4R)-4-[(3R,5S,7S,8R,9S,10S,13R,14S,17R)-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid
128-13-2
17-beta-(1-Methyl-3-carboxypropyl)etiocholane-3-alpha,7-beta-diol
3 alpha,7 beta-Dihydroxy-5 beta-cholan-24-oic Acid
3,7-Dihydroxycholan-24-oic acid
3-alpha,7-beta-Dihydroxy-5-beta-cholanoic acid
3-alpha,7-beta-Dihydroxycholanic acid
3-alpha,7-beta-Dioxycholanic acid
3a,7b-Dihydroxy-5b-cholan-24-oate
3a,7b-Dihydroxy-5b-cholan-24-oic acid
3alpha,7beta-Dihydroxy-5beta-cholan-24-oic acid
3alpha,7beta-Dihydroxy-5beta-cholanic acid
4-10-00-01604 (Beilstein Handbook Reference)
50809-41-1
5beta-Cholan-24-oic acid-3alpha,7beta-diol
5beta-Cholanic Acid-3alpha,7beta-diol
7-beta-Hydroxylithocholic acid
7beta-Hydroxylithocholic acid
80225-86-1
AB00513977
AC-18919
AC-2081
AC1L1LJH
Acide ursodesoxycholique
Acide ursodesoxycholique [INN-French]
Acido ursodeossicolico
Acido ursodeossicolico [Italian]
Acido ursodeoxicolico
Acido ursodeoxicolico [INN-Spanish]
Acidum ursodeoxycholicum
Acidum ursodeoxycholicum [INN-Latin]
Actigall
Actigall (TN)
Antigall
Arsacol
BB_NC-2372
BPBio1_001052
BRN 3219888
BSPBio_000956
C07880
C24H40O4
CCRIS 5502
CHEBI:9907
CHEMBL1551
CHEMBL73390
CID11516715
CID31401
CPD-10534
CPD000058403
Cholan-24-oic acid, 3,7-dihydroxy-, (3-alpha,5-beta,7-beta)- (9CI)
Cholit-ursan
D00734
DB01586
Delursan
Deoxyursocholic Acid
Destolit
Deursil
Dom-ursodiol c
EINECS 204-879-3
HMS1570P18
 
ISO-URSODEOXYCHOLIC ACID
IU5
LMST04010033
LS-53033
Litursol
Lyeton
MLS000028461
MLS001066373
MolPort-001-794-630
MolPort-005-932-884
NCGC00179363-01
NCI60_028904
NSC 657950
NSC 683769
PHL-ursodiol c
PMS-ursodiol c
Peptarom
Prestwick0_000958
Prestwick1_000958
Prestwick2_000958
Prestwick3_000958
S1643_Selleck
SAM002264653
SMP2_000012
SMR000058403
SPBio_003105
Sodium Ursodeoxycholate
Solutrat
U-9000
U0030
U5127_SIGMA
UDCA
UDCS
UNII-724L30Y2QR
URSODEOXYCHOLIC ACID
UrSO
Urosdesoxycholate
Urosdesoxycholic acid
Urosiol
Ursacholic Acid
Ursacol
Urso
Urso (TN)
Urso 250
Urso DS
Urso Forte
Ursobilin
Ursochol
Ursodamor
Ursodeoxy cholic acid
Ursodeoxycholate
Ursodeoxycholic acid
Ursodeoxycholic acid (JP15/INN)
Ursodeoxycholic acid, UDCA, Ursosan, Ursofalk, Urso Forte, Udiliv, Ursodiol
Ursodeoxycholicacid
Ursodesoxycholic acid
Ursodexycholate
Ursodexycholic Acid
Ursodexycholic acid
Ursodiol
Ursodiol (USP)
Ursodiol [USAN]
Ursofalk
Ursolvan
Ursosan
chenodeoxycholic acid
ursodeoxycholate
ursodiol
39
CarboplatinapprovedPhase 3, Phase 2, Phase 1205041575-94-410339178, 498142, 38904
Synonyms:
(SP-4-2)-diammine[cyclobutane-1,1-dicarboxylato(2-)-kappa(2)O,O']platinum
/h1-3H2,(H,7,8)(H,9,10)
/q
1,1-Cyclobutanedicarboxylate diammine platinum (II)
1,1-Cyclobutanedicarboxylate diammine platinum(II)
2*-1
2*1H2
41575-94-4
70903-55-8
AC-1457
AC1L8I6U
Ambap41575-94-4
BSPBio_003145
C 2538
C2043
C2538_SIGMA
C6H10N2O4Pt
CBDCA
CCRIS 3404
CHEBI:31355
CHEMBL1351
CHEMBL288376
CID10339178
CID2567
CID38904
CID426756
CID498142
CID5352133
CID6398587
CID6603770
Carbopaltin
Carboplatin
Carboplatin (JAN/USP/INN)
Carboplatin (USAN)
Carboplatin [USAN:INN:BAN:JAN]
Carboplatine
Carboplatine [French]
Carboplatino
Carboplatino [Spanish]
Carboplatinum
Carboplatinum [Latin]
Cbdca
Cyclobutane-1,1-dicarboxylate
D01363
DB00958
Diammine(1,1-cyclobutanedicarboxylato)platinum (II)
Diammine(cyclobutane-1,1-dicarboxylato(2-)-O,O')platinum
Diammine-1,1-cyclobutane dicarboxylate platinum II
DivK1c_000892
EINECS 255-446-0
EU-0100230
Ercar
HMS1921J16
HMS2090M05
HMS2092B22
HMS502M14
HSDB 6957
I14-2390
IDI1_000892
IUPAC: Azane
InChI=1/C6H8O4.2H2N.Pt/c7-4(8)6(5(9)10)2-1-3-6
 
JM 8
JM-8
KBio1_000892
KBio2_002009
KBio2_004577
KBio2_007145
KBio3_002645
KBioGR_000713
KBioSS_002009
LS-117689
Lopac-C-2538
Lopac0_000230
MolPort-003-665-501
MolPort-003-845-609
NCGC00015223-01
NCGC00093695-01
NCGC00094961-01
NCGC00094961-02
NCGC00094961-03
NCGC00162099-01
NCGC00162099-02
NCGC00167800-01
NCGC00178242-01
NINDS_000892
NSC 201345
NSC 241240
NSC-241240
NSC201345
NSC241240
Paraplatin
Paraplatin (TN)
Paraplatin, Carboplatin
Paraplatin-AQ
Platinum(+2) Cation
Platinum(II), (1, 1-cyclobutanedicar
Platinum, diammine(1,1-cyclobutanedicarboxylato(2-)-O,O')-, (SP-4-2)
Platinum, {diammine[1,1-cyclobut
S1215_Selleck
SPBio_000716
SPECTRUM1502106
Spectrum2_000898
Spectrum3_001503
Spectrum4_000337
Spectrum5_001094
Spectrum_001529
UNII-BG3F62OND5
azanide
carboplatin
cis -Diammine[1,1-cyclobutane-dicarboxylato] platinum
cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(II)
cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(ii)
cis-Diamine(1,1-cyclobutanedicarboxylato)platinum(II)
cis-Diamine[1,1-cyclobutanedicarboxylato]platinum(II)
cis-Diammine(1,1-cyclobutanedicarboxylato) platinum
cis-Diammine(1,1-cyclobutanedicarboxylato)platinum
cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II)
cis-Diammine(cyclobutanedicarboxylato)platinum II
cyclobutane-1,1-dicarboxylic acid
diammine[cyclobutane-1,1-dicarboxylato(2-)-k2O1,O1]platinum
nchembio.573-comp10
nchembio773-comp2
nchembio873-comp3
platinum(2+)
40
SuccinylcholineapprovedPhase 3, Phase 1169306-40-15314
Synonyms:
2,2'-[(1,4-DIOXOBUTANE-1,4-DIYL)BIS(OXY)]BIS(N,N,N-TRIMETHYLETHANAMINIUM)
2,2'-[(1,4-DIOXOBUTANE-1,4-diyl)bis(oxy)]bis(N,N,N-trimethylethanaminium)
2ha2
2ha6
306-40-1
4-04-00-01451 (Beilstein Handbook Reference)
541-19-5 (diiodide)
55-94-7 (dibromide)
71-27-2 (dichloride)
AC1L1K2T
Anectine
BRN 1805311
C07546
C14H30N2O4
CHEBI:45652
CHEMBL703
CID5314
Choline, succinate (2:1) (ester)
Choline, succinate (ester)
DB00202
Diacetylcholine
Dicholine succinate
Ditilin
Ditiline
HMS2090P14
HSDB 3254
InChI=1/C14H30N2O4/c1-15(2,3)9-11-19-13(17)7-8-14(18)20-12-10-16(4,5)6/h7-12H2,1-6H3/q+2
L000926
LS-53328
Listenon
 
Lopac-S-8251
Lopac0_001080
Lysthenon
MolPort-002-964-486
NCGC00015971-01
NCGC00015971-03
NCGC00162336-01
Quelicin
Quelicin Preservative Free
SCK
ST50437287
STK177290
Scoline
Succicuran
Succinic acid, diester with choline
Succinic acid, diester with choline chloride
Succinocholine
Succinoylcholine
Succinyl choline
Succinylbischoline
Succinylcholine
Succinylcholine Chloride
Succinyldicholine
Sucostrin
Suxamethonium
Suxamethonium chloride
UNII-J2R869A8YF
ZINC01530820
succinylcholine
succinyldicholine
trimethyl-[2-[4-oxo-4-(2-trimethylazaniumylethoxy)butanoyl]oxyethyl]azanium diio
trimethyl-[2-[4-oxo-4-[2-(trimethylazaniumyl)ethoxy]butanoyl]oxyethyl]azanium
41
leucovorinapproved, NutraceuticalPhase 3, Phase 2, Phase 1323558-05-954575, 6560146, 143
Synonyms:
(5-formyl-5,6,7,8-tetrahydropteroyl)glutamate
(6R,S)-5-Formyltetrahydrofolate
10-Formyl-7,8-dihydrofolate
10-Formyl-7,8-dihydrofolic acid
5-Formyl-5,6,7,8-tetrahydrofolate
5-Formyl-5,6,7,8-tetrahydrofolic acid
5-Formyl-5,6,7,8-tetrahydropteroyl-L-glutamic acid
5-Formyltetrahydrofolate
5-Formyltetrahydrofolic acid
5-Formyltetrahydropteroylglutamate
5-Formyltetrahydropteroylglutamic acid
5-formyltetrahydrofolic acid
Acide folinique
Calcium citrovorum factor
Calcium folinate
Citrovorum factor
Folinate
Folinic acid
Folinic acid calcium salt
 
Folinic acid calcium salt USP27
Folinic acid-SF
L(-)-5-Formyl-5,6,7,8-tetrahydrofolic acid
L-Leucovorin
L-N-[p-[[(2-Amino-5-formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl)methyl]amino]benzoyl]-Glutamic acid
L-leucovorin
Leucal
Leucovorin calcium
Leucovorin folinic acid
Leucovorinum
Leukovorin
Levoleucovorin
N-(5-formyl-5,6,7,8-tetrahydropteroyl)-L-glutamic acid
N5-Formyl-5,6,7,8-tetrahydrofolate
N5-Formyl-5,6,7,8-tetrahydrofolic acid
N5-Formyl-THF
N5-Formyltetrahydrofolate
N5-Formyltetrahydrofolic acid
Welcovorin
Wellcovorin
folinate
42
Folic Acidapproved, nutraceutical, vet_approvedPhase 3, Phase 2, Phase 1439259-30-36037
Synonyms:
(2S)-2-[[4-[(2-amino-4-oxo-1H-pteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid
01769_FLUKA
2d0k
33609-88-0
36653-55-1 (mono-potassium salt)
59-30-3
6484-89-5 (mono-hydrochloride salt)
AC-11682
AC1L1LNX
AI3-26387
AKOS000503224
ARONIS014410
Acfol (Spain)
Acide folique
Acide folique [INN-French]
Acido folico
Acido folico [INN-Spanish]
Acidum folicum
Acidum folicum [INN-Latin]
Acifolic
Antianemia factor
Apo-Folic
BIDD:ER0563
BIDD:GT0641
BIF0608
BPBio1_000654
BSPBio_000594
BSPBio_002338
C00504
C20H20N6O6
CAS-59-30-3
CCRIS 666
CHEBI:27470
CHEMBL1622
CID6037
CPD000471860
Cytofol
D00070
DB00158
DivK1c_000494
Dosfolat B activ
EINECS 200-419-0
F0043
F7876_SIAL
F7876_SIGMA
F8758_SIGMA
F8798_SIAL
F8890_SIGMA
FOL
Facid
Factor U
Folacid
Folacin
Folaemin
Folaemin [Netherlands]
Folan
Folasic (Australia)
Folate
Folbal
Folcidin
Folcidin (VAN)
Folcysteine
Foldine
Foldine [France]
Folettes
Foliamin
Folic
Folic acid
Folic acid (JP15/USP/INN)
Folic acid (TN)
Folic acid [BAN:INN:JAN]
Folic acid [INN:BAN:JAN]
Folic acid dihydrate
Folicet
Folicet (TN)
Folico
Folico (Italy)
Folina
Folina (Italy)
Folipac
Folsaeure
 
Folsan
Folsaure
Folsav
Folvite
Folvron
Glutamic acid, N-(p-(((2-amino-4-hydroxypyrimido(4,5-b)pyrazin-6-yl)methyl)amino)benzoyl)-, L
HMS1921D20
HMS2092N17
HMS501I16
HSDB 2002
IDI1_000494
InChI=1/C19H19N7O6/c20-19-25-15-14(17(30)26-19)23-11(8-22-15)7-21-10-3-1-9(2-4-10)16(29)24-12(18(31)32)5-6-13(27)28/h1-4,8,12,21H,5-7H2,(H,24,29)(H,27,28)(H,31,32)(H3,20,22,25,26,30)/t12-/m0/s
Incafolic
KBio1_000494
KBio2_001861
KBio2_004429
KBio2_006997
KBio3_001558
KBioGR_002222
KBioSS_001861
Kyselina listova
Kyselina listova [Czech]
LS-2157
Liver Lactobacillus casei factor
MLS001304016
MLS001335861
Millafol
Mission prenatal
Mittafol
MolPort-004-285-551
N-(4-(((2-Amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzo- yl)-L-glutamic acid
N-(4-((2-Amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzoyl)-L-glutamic acid
N-(4-{[(2-Amino-4-oxo-3,4-dihydropteridin-6-yl)methyl]amino}benzoyl)-L-glutamic acid
N-(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}benzoyl)-L-glutamic acid
N-(p-(((2-Amino-4-hydroxy-6-pteridinyl)methyl)amino)benzoyl)-L-glutamic acid
N-Pteroyl-L-glutamic acid
N-[(4-{[(2-Amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamic acid
N-[(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamic acid
N-[4-[[(2-Amino-3,4-dihydro-4-oxo-6-pteridinyl)methyl]amino]benzoyl]-L-glutamic acid
NCGC00016265-01
NCGC00142391-01
NINDS_000494
NSC 3073
Nifolin
Nifolin [Denmark]
Novofolacid
Novofolacid [Canada]
PGA
PGA (VAN)
Prestwick3_000627
Prestwick_230
PteGlu
Pteroyl-L-glutamate
Pteroyl-L-glutamic acid
Pteroyl-L-monoglutamate
Pteroyl-L-monoglutamic acid
Pteroylglutamate
Pteroylglutamic acid
Pteroylmonoglutamate
Pteroylmonoglutamic acid
SAM002264616
SDCCGMLS-0066738.P001
SMP2_000137
SMR000471860
SPBio_001357
SPECTRUM1502020
Serum Folate Level
Spectrum2_001459
Spectrum3_000749
Spectrum4_001751
Spectrum5_000602
Spectrum_001381
UNII-935E97BOY8
Usaf cb-13
Vitamin B11
Vitamin B9
Vitamin Bc
Vitamin Be
Vitamin M
bmse000299
folic acid
nchembio.108-comp10
43Antibiotics, AntitubercularPhase 3, Phase 2, Phase 17180
44Anti-Bacterial AgentsPhase 3, Phase 2, Phase 111226
45Alkylating AgentsPhase 2, Phase 3, Phase 14827
46Antineoplastic Agents, AlkylatingPhase 2, Phase 3, Phase 14603
47VaccinesPhase 3, Phase 1, Phase 26611
48VitaminsPhase 3, Phase 2, Phase 15282
49Trace ElementsPhase 3, Phase 2, Phase 16001
50MicronutrientsPhase 3, Phase 2, Phase 16001

Interventional clinical trials:

(show top 50)    (show all 311)
idNameStatusNCT IDPhase
1Quality of Life in Patients With Unresectable Hilar Cholangiocarcinoma on Palliative Metallic Stent Versus Plastic StentUnknown statusNCT00746538Phase 4
2Preoperative Biliary Drainage for Resectable Hilar CholangiocarcinomaUnknown statusNCT00797121Phase 4
3Uncovered Self-expandable Metal Stent Versus Double Layer Plastic Stent for Malignant Hilar StrictureUnknown statusNCT01125865Phase 4
4Efficacy and Cost Analysis of Plastic Stent Compare to Metallic Stent in Hilar CholangiocarcinomaCompletedNCT00721175Phase 4
5Influence of an Oral Nutritional Supplement Rich in Omega-3 Fatty Acids on Functional State and Quality of Life in Malnourished Patients With Gastroenterological TumorsCompletedNCT00168987Phase 4
6Etomidate vs. Midazolam for Sedation During ERCPCompletedNCT02027311Phase 4
7Anesthetic Agents and Acute Kidney Injury After Liver Resection SurgeryRecruitingNCT02174575Phase 4
8Early Oral Versus Enteral Nutrition After PancreatoduodenectomyRecruitingNCT01642875Phase 4
9Stereotactic Body Radiotherapy for Liver TumorsActive, not recruitingNCT01347333Phase 4
10Percutaneous Bilateral Versus Unilateral Metal Stent for Hilar CholangiocarcinomaUnknown statusNCT02108145Phase 2, Phase 3
11Comparison of Endoscopic Radiofrequency Ablation Versus Photodynamic Therapy for Inoperable CholangiocarcinomaUnknown statusNCT01739465Phase 2, Phase 3
12RFA RCT for Pancreatic or Bile Duct CancerUnknown statusNCT02166190Phase 3
13Unilateral Versus Bilateral Stents for Bismuth Type II and III Malignant Hilar StricturesUnknown statusNCT00653978Phase 3
14S-1 and Photodynamic Therapy in CholangiocarcinomaCompletedNCT00869635Phase 3
15Gemcitabine With or Without Cisplatin in Treating Patients With Unresectable Locally Advanced or Metastatic Cholangiocarcinoma or Other Biliary Tract TumorsCompletedNCT00262769Phase 3
16Biliary Stenting With or Without Photodynamic Therapy in Treating Patients With Locally Advanced, Recurrent, or Metastatic Cholangiocarcinoma or Other Biliary Tract Tumors That Cannot Be Removed by SurgeryCompletedNCT00513539Phase 3
17Trial of High-dose Urso in Primary Sclerosing CholangitisCompletedNCT00059202Phase 2, Phase 3
18Capecitabine or Observation After Surgery in Treating Patients With Biliary Tract CancerCompletedNCT00363584Phase 3
19Gemcitabine Hydrochloride and Oxaliplatin or Observation in Treating Patients With Biliary Tract Cancer That Has Been Removed by SurgeryCompletedNCT01313377Phase 3
20Comprehensive Electronic Cancer Support System for the Treatment of Cancer Related SymptomsCompletedNCT01640522Phase 3
21Oxaliplatin+Gemcitabine vs Capecitabine as Adjuvant Therapy for Intrahepatic CholangiocarcinomaRecruitingNCT02548195Phase 3
22Chemo Alone or in Combination With Radiation in Unresectable CholangiocarcinomaRecruitingNCT02773485Phase 3
23Study of AG-120 in Previously Treated Advanced Cholangiocarcinoma With IDH1 Mutations (ClarIDHy)RecruitingNCT02989857Phase 3
24Photodynamic Therapy (PDT) for Palliation of CholangiocarcinomaRecruitingNCT01755013Phase 2, Phase 3
25Adjuvant Chemotherapy With Gemcitabine and Cisplatin Compared to Observation After Curative Intent Resection of Biliary Tract CancerRecruitingNCT02170090Phase 3
26Clinical Trial of Adjuvant Chemotherapy Followed by Concurrent Chemoradiotherapy Compared With Adjuvant Chemotherapy Alone in Patients With Gallbladder Carcinoma and Extrahepatic CholangiocarcinomaRecruitingNCT02798510Phase 3
27Endoscopic Biliary Radiofrequency Ablation of Malignant Distal Common Bile Duct StricturesRecruitingNCT01721174Phase 2, Phase 3
28Study of GEMOX(Gemcitabine/Oxaliplatin) Versus XELOX(Xeloda/Oxaliplatin) in Advanced Biliary Tract CarcinomaRecruitingNCT01470443Phase 3
29Active Symptom Control Alone or With mFOLFOX Chemotherapy for Locally Advanced/ Metastatic Biliary Tract CancersRecruitingNCT01926236Phase 3
30Liver Cancer Immunotherapy: Placebo-controlled Clinical Trial of Hepcortespenlisimut-LRecruitingNCT02232490Phase 3
31Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for the Patients With CholangiocarcinomaActive, not recruitingNCT02482454Phase 2, Phase 3
32Gemcitabine Hydrochloride and Cisplatin With or Without Radiation Therapy in Treating Patients With Localized Liver Cancer That Cannot Be Removed by SurgeryActive, not recruitingNCT02200042Phase 3
33A Study of Cisplatin or Carboplatin With Gemcitabine Versus Gemcitabine Alone as Adjuvant Therapy in Patients With Resected or Ablation Intra-Hepatic CholangiocarcinomaNot yet recruitingNCT03081039Phase 3
34Percutaneous Hepatic Perfusion vs. Cisplatin/Gemcitabine in Patients With Intrahepatic CholangiocarcinomaNot yet recruitingNCT03086993Phase 2, Phase 3
35Safety and Efficiency of Photodynamic Therapy for Blie Duct CarcinomaSuspendedNCT01859169Phase 2, Phase 3
36Photodynamic Therapy (PDT) Trial for Palliation of CholangiocarcinomaTerminatedNCT00907413Phase 3
37Efficiency Evaluation of Photodynamic Therapy With Photofrin® on Unresectable Type III or IV CholangiocarcinomasTerminatedNCT00540735Phase 3
38Efficacy and Safety Study of PDT Using Photofrin in Unresectable Advanced Perihilar Cholangiocarcinoma (OPUS)TerminatedNCT02082522Phase 3
39XL119 Versus 5-Fluorouracil (5-FU) Plus Leucovorin (LV) in Subjects With Advanced Biliary TumorsTerminatedNCT00090025Phase 3
40Stent Placement With or Without Photodynamic Therapy Using Porfimer Sodium as Palliative Treatment in Treating Patients With Stage III or Stage IV Cholangiocarcinoma That Cannot Be Removed By SurgeryWithdrawnNCT00253617Phase 3
41Comparison Between Two Methods of Bilateral Stenting for Malignant Hilar ObstructionWithdrawnNCT01622803Phase 3
42Calcitriol in Advanced Intrahepatic CholangiocarcinomaUnknown statusNCT01039181Phase 2
43Single Arm Study of RAD001 as Monotherapy in Treatment in Advanced CholangiocarcinomaUnknown statusNCT01525719Phase 2
44Study of RAD001 in Advanced Cholangiocarcinoma: RADiCholUnknown statusNCT00973713Phase 2
45Safety Study of Liver Transplantation for Hilar CholangiocarcinomaUnknown statusNCT02178280Phase 1, Phase 2
46Regorafenib Versus Placebo to Treat CholangiocarcinomaUnknown statusNCT02162914Phase 2
47Intra-hepatic Chemotherapy in Patient With Non-resectable Liver Metastases From CholangiocarcinomaUnknown statusNCT01247337Phase 2
48Melphalan for Use With the Hepatic Delivery System Treatment in Patients With Unresectable Hepatocellular Carcinoma or Intra Hepatic CholangiocarcinomaUnknown statusNCT02415036Phase 2
49PiCCA Study (Panitumumab in Combination With Cisplatin/Gemcitabine)Unknown statusNCT01320254Phase 2
50The Adoptive Immunotherapy for Solid Tumors Using Modified Autologous Cytokine-induced Killer CellsUnknown statusNCT01868490Phase 1, Phase 2

Search NIH Clinical Center for Cholangiocarcinoma, Susceptibility to

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Stem-cell-based therapeutic approaches for Cholangiocarcinoma, Susceptibility to:
Tumor infiltrating lymphocytes (TILs) for solid tumors
Embryonic/Adult Cultured Cells Related to Cholangiocarcinoma, Susceptibility to:
Tumor infiltrating lymphocytes, PMIDs: 24329789, 19342963, 23904171, 21498393, 22996367, 19304471, 22555974, 15800326, 23650429, 21325070, 24218514, 8170938, 12242449

Genetic Tests for Cholangiocarcinoma, Susceptibility to

About this section

Genetic tests related to Cholangiocarcinoma, Susceptibility to:

id Genetic test Affiliating Genes
1 Cholangiocarcinoma, Susceptibility to27
2 Cholangiocarcinoma24 PTPN3

Anatomical Context for Cholangiocarcinoma, Susceptibility to

About this section

MalaCards organs/tissues related to Cholangiocarcinoma, Susceptibility to:

36
Liver, Small intestine

Publications for Cholangiocarcinoma, Susceptibility to

About this section

Variations for Cholangiocarcinoma, Susceptibility to

About this section

Cosmic variations for Cholangiocarcinoma, Susceptibility to:

8 (show top 50)    (show all 426)
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1COSM521KRASbiliary tract,bile duct,carcinoma,adenocarcinomac.35G>Ap.G12D11
2COSM520KRASbiliary tract,bile duct,carcinoma,adenocarcinomac.35G>Tp.G12V11
3COSM14169SMAD4biliary tract,bile duct,carcinoma,adenocarcinomac.988G>Ap.E330K11
4COSM28747IDH1biliary tract,bile duct,carcinoma,adenocarcinomac.394C>Tp.R132C11
5COSM516KRASbiliary tract,bile duct,carcinoma,adenocarcinomac.34G>Tp.G12C11
6COSM143890AXIN1biliary tract,bile duct,carcinoma,adenocarcinomac.943G>Ap.A315T11
7COSM10659TP53biliary tract,bile duct,carcinoma,adenocarcinomac.817C>Tp.R273C11
8COSM308282KMT2Cbiliary tract,bile duct,carcinoma,adenocarcinomac.13080G>Ap.W4360*11
9COSM476BRAFbiliary tract,bile duct,carcinoma,adenocarcinomac.1799T>Ap.V600E11
10COSM28750IDH1biliary tract,bile duct,carcinoma,adenocarcinomac.395G>Tp.R132L11
11COSM517KRASbiliary tract,bile duct,carcinoma,adenocarcinomac.34G>Ap.G12S11
12COSM19826CDH1biliary tract,bile duct,carcinoma,adenocarcinomac.532-1G>Cp.?11
13COSM307989ADAM12biliary tract,bile duct,carcinoma,adenocarcinomac.2104C>Tp.R702W11
14COSM22954EGFRbiliary tract,bile duct,carcinoma,adenocarcinomac.2324G>Ap.C775Y11
15COSM14140SMAD4biliary tract,bile duct,carcinoma,adenocarcinomac.1081C>Tp.R361C11
16COSM308146SEMA5Abiliary tract,bile duct,carcinoma,adenocarcinomac.2170C>Ap.H724N11
17COSM532KRASbiliary tract,bile duct,carcinoma,adenocarcinomac.38G>Ap.G13D11
18COSM22932FBXW7biliary tract,bile duct,carcinoma,adenocarcinomac.1393C>Tp.R465C11
19COSM468BRAFbiliary tract,bile duct,carcinoma,adenocarcinomac.1785T>Gp.F595L11
20COSM19770CDH1biliary tract,bile duct,carcinoma,adenocarcinomac.1027C>Tp.L343L11
21COSM28749IDH1biliary tract,bile duct,carcinoma,adenocarcinomac.394C>Gp.R132G11
22COSM527KRASbiliary tract,bile duct,carcinoma,adenocarcinomac.37G>Tp.G13C11
23COSM13543CDKN2Abiliary tract,bile duct,carcinoma,adenocarcinomac.47T>Cp.L16P11
24COSM44309TP53biliary tract,bile duct,carcinoma,adenocarcinomac.440T>Gp.V147G11
25COSM522KRASbiliary tract,bile duct,carcinoma,adenocarcinomac.35G>Cp.G12A11
26COSM584NRASbiliary tract,bile duct,carcinoma,adenocarcinomac.182A>Gp.Q61R11
27COSM6252EGFRbiliary tract,bile duct,carcinoma,adenocarcinomac.2155G>Ap.G719S11
28COSM45393TP53biliary tract,bile duct,carcinoma,adenocarcinomac.793C>Ap.L265M11
29COSM28748IDH1biliary tract,bile duct,carcinoma,adenocarcinomac.394C>Ap.R132S11
30COSM470BRAFbiliary tract,bile duct,carcinoma,adenocarcinomac.1789C>Gp.L597V11
31COSM10722TP53biliary tract,bile duct,carcinoma,adenocarcinomac.853G>Ap.E285K11
32COSM10654TP53biliary tract,bile duct,carcinoma,adenocarcinomac.637C>Tp.R213*11
33COSM10812TP53biliary tract,bile duct,carcinoma,adenocarcinomac.722C>Tp.S241F11
34COSM34039IDH2biliary tract,bile duct,carcinoma,adenocarcinomac.514A>Tp.R172W11
35COSM1578128EGFRbiliary tract,bile duct,carcinoma,adenocarcinomac.2475G>Ap.M825I11
36COSM143900AXIN1biliary tract,bile duct,carcinoma,adenocarcinomac.19G>Ap.G7S11
37COSM518KRASbiliary tract,bile duct,carcinoma,adenocarcinomac.34G>Cp.G12R11
38COSM10727TP53biliary tract,bile duct,carcinoma,adenocarcinomac.438G>Ap.W146*11
39COSM10660TP53biliary tract,bile duct,carcinoma,adenocarcinomac.818G>Ap.R273H11
40COSM45050TP53biliary tract,bile duct,carcinoma,adenocarcinomac.871A>Gp.K291E11
41COSM10656TP53biliary tract,bile duct,carcinoma,adenocarcinomac.742C>Tp.R248W11
42COSM10883TP53biliary tract,bile duct,carcinoma,adenocarcinomac.731G>Ap.G244D11
43COSM43909TP53biliary tract,bile duct,carcinoma,adenocarcinomac.817C>Ap.R273S11
44COSM308280KMT2Cbiliary tract,bile duct,carcinoma,adenocarcinomac.9934C>Tp.Q3312*11
45COSM143853AXIN1biliary tract,bile duct,carcinoma,adenocarcinomac.236C>Tp.T79I11
46COSM44226TP53biliary tract,bile duct,carcinoma,adenocarcinomac.380C>Tp.S127F11
47COSM10648TP53biliary tract,bile duct,carcinoma,adenocarcinomac.524G>Ap.R175H11
48COSM308173TRIM28biliary tract,bile duct,carcinoma,adenocarcinomac.1475G>Tp.R492L11
49COSM10687TP53biliary tract,bile duct,carcinoma,adenocarcinomac.527G>Ap.C176Y11
50COSM10893TP53biliary tract,bile duct,carcinoma,adenocarcinomac.824G>Ap.C275Y11

Copy number variations for Cholangiocarcinoma, Susceptibility to from CNVD:

6
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1111150173509791835138441Copy numberERBB2Cholangiocarcinoma
21180161775124447519279Copy numberP53Cholangiocarcinoma
3159441214260000048129895AmplificationTFF1Cholangiocarcinoma
4159442214260000048129895AmplificationTFF2Cholangiocarcinoma
5159443214260000048129895AmplificationTFF3Cholangiocarcinoma

Expression for genes affiliated with Cholangiocarcinoma, Susceptibility to

About this section
Search GEO for disease gene expression data for Cholangiocarcinoma, Susceptibility to.

Pathways for genes affiliated with Cholangiocarcinoma, Susceptibility to

About this section

Pathways related to Cholangiocarcinoma, Susceptibility to according to GeneCards Suite gene sharing:

(show all 12)
idSuper pathwaysScoreTop Affiliating Genes
1
Show member pathways
9.8CDH1, MET, PTPN3
29.7CDH1, ERBB2, MET
39.7CDH1, ERBB2, MET
49.6CDH1, MET, NCAM1
59.4KRT19, KRT8, PTGS2
6
Show member pathways
9.1MUC1, MUC2, MUC4, MUC5AC
7
Show member pathways
9.1MUC1, MUC2, MUC4, MUC5AC
8
Show member pathways
9.1MUC1, MUC2, MUC4, MUC5AC
99.1CDH1, ERBB2, MET, PTGS2, VEGFC
108.9AFP, CDX2, KRT19, MET, NCAM1
11
Show member pathways
8.9GPC3, MUC1, MUC2, MUC4, MUC5AC
128.5CDH1, KRT19, KRT20, KRT7, KRT8, MUC1

GO Terms for genes affiliated with Cholangiocarcinoma, Susceptibility to

About this section

Cellular components related to Cholangiocarcinoma, Susceptibility to according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1Golgi lumenGO:00057969.5GPC3, MUC1, MUC2, MUC4, MUC5AC
2intermediate filamentGO:00058828.9KRT19, KRT20, KRT7, KRT8
3extracellular regionGO:00055768.3AFP, CDH1, GPC3, MET, MUC1, MUC4

Biological processes related to Cholangiocarcinoma, Susceptibility to according to GeneCards Suite gene sharing:

(show all 7)
idNameGO IDScoreTop Affiliating Genes
1entry of bacterium into host cellGO:003563510.6CDH1, MET
2maintenance of gastrointestinal epitheliumGO:003027710.5MUC2, MUC4
3cell differentiation involved in embryonic placenta developmentGO:006070610.3KRT19, KRT8
4O-glycan processingGO:00162669.7MUC1, MUC2, MUC4, MUC5AC
5cornificationGO:00702689.6KRT19, KRT20, KRT7, KRT8
6keratinizationGO:00314249.5KRT19, KRT20, KRT7, KRT8
7stimulatory C-type lectin receptor signaling pathwayGO:00022239.1MUC1, MUC2, MUC4, MUC5AC

Sources for Cholangiocarcinoma, Susceptibility to

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
27GTR
28HGMD
29HMDB
30ICD10
31ICD10 via Orphanet
32ICD9CM
33IUPHAR
34KEGG
37MedGen
39MeSH
40MESH via Orphanet
41MGI
44NCI
45NCIt
46NDF-RT
49NINDS
50Novoseek
52OMIM
53OMIM via Orphanet
57PubMed
58QIAGEN
63SNOMED-CT via Orphanet
67Tumor Gene Family of Databases
68UMLS
69UMLS via Orphanet